If you developed Guillain-Barré syndrome after a Shingrix shot, a Shingrix Guillain-Barré lawsuit is a civil product liability claim filed directly against GlaxoSmithKline in state or federal court. It is not a vaccine court case. The federal no-fault program that handles most vaccine injuries does not cover shingles vaccines, which is why these claims land in ordinary civil litigation with all the burdens that carries.
Why Shingrix Cases Aren’t Filed in Vaccine Court
The Vaccine Injury Compensation Program handles most U.S. vaccine injury claims through the Court of Federal Claims. It only covers vaccines on its Vaccine Injury Table, and the federal government’s covered-vaccine list is explicit: “Herpes zoster (shingles) vaccine is not a VICP-covered vaccine.”1HRSA. Covered Vaccines
That exclusion changes everything about how a Shingrix claim proceeds. VICP cases go before special masters in a streamlined process, and the program pays attorneys’ fees even when a claim fails. A civil suit against GSK is the opposite: adversarial discovery, expert battles, and a heavier burden of proof resting on the person who was injured.2Green Legal Team. Vaccine Injury FAQ
What the Lawsuits Allege
The core legal theory is failure to warn. Shingrix was approved on October 20, 2017, based on 17 clinical studies of roughly 17,000 adults, none of which flagged an increased GBS risk.3U.S. Food and Drug Administration. FDA Requires Warning About Guillain-Barré Syndrome Be Included in Prescribing Information for Shingrix The signal only appeared after millions of doses were given.
On March 24, 2021, the FDA required GSK to add a GBS warning to the Shingrix prescribing information, noting the elevated risk during the 42 days after vaccination.4DailyMed. Shingrix Prescribing Information That means Shingrix carried no GBS warning for more than three years while on the U.S. market. Plaintiffs vaccinated during that window can argue that neither they nor their prescribing doctors were told about a risk the manufacturer knew or should have known about.
The Science Plaintiffs Point To
An FDA/CDC/CMS observational study analyzing about 3.73 million Shingrix doses given to Medicare beneficiaries aged 65 and older between October 2017 and February 2020 estimated three excess GBS cases per million doses, rising to about six excess cases per million after the first dose. No increased risk was seen after the second dose. Shingrix recipients had a GBS rate roughly two to five times higher than recipients of the older Zostavax vaccine, depending on the analytic method.3U.S. Food and Drug Administration. FDA Requires Warning About Guillain-Barré Syndrome Be Included in Prescribing Information for Shingrix5PubMed. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries
A second Medicare study estimated a higher rate: about seven excess cases per million doses overall and 12 after the first dose. GSK’s current prescribing information references both studies and states that their results “suggest a causal association of GBS with SHINGRIX.”6GSKPro. Shingrix Prescribing Information A March 2026 study in Drug Safety, examining 3,383,799 Medicare beneficiaries vaccinated between 2018 and 2020, identified 75 new-onset GBS cases, a relative risk of 3.15, and 6.59 excess cases per million doses, again concentrated after the first dose.7Springer. Guillain–Barré Syndrome Following Recombinant Zoster Vaccine in US Medicare Adults Age 65 Years or Older
On the biological side, researchers have hypothesized that the QS-21 component of Shingrix’s AS01 adjuvant may trigger immune cross-reactivity through molecular mimicry, in which the immune system attacks nerve tissue that structurally resembles vaccine components.8Rocky Vista University. Shingrix Vaccine and Neurological Adverse Events That mechanism is a hypothesis, not established fact.9PubMed Central. Neurological Adverse Events Following Recombinant Zoster Vaccine
The FDA’s position, when it required the label change, was that “available evidence is insufficient to establish a causal relationship,” and GSK has said it “remains confident in the favorable benefit-risk profile of Shingrix.”3U.S. Food and Drug Administration. FDA Requires Warning About Guillain-Barré Syndrome Be Included in Prescribing Information for Shingrix10Fierce Pharma. FDA Slaps New Warning on GlaxoSmithKline’s Vaccine Shingrix Based on Postmarketing Findings Expect GSK to make the same argument in court.
Causation Is the Hard Part
Even with the epidemiology, an individual plaintiff still has to prove that their GBS was caused by the vaccine and not by something else. GBS is rare regardless of vaccination and most commonly follows a bacterial or viral infection, which gives defendants a ready alternative explanation to raise for almost any plaintiff.
The plaintiff’s toolkit is the postmarketing evidence: the statistical association across multiple Medicare studies, the 42-day risk window that matches the biology of an immune reaction, the dose-response pattern where risk concentrates after the first shot, and the molecular mimicry hypothesis for the AS01 adjuvant. Whether any of that is enough to prove specific causation for a particular person is the fight that will decide these cases.
How Long You Have to File
There is no single national filing deadline. Because these are ordinary civil claims, the statute of limitations depends on the law of the state where you live or were vaccinated. Most states use a discovery rule, meaning the clock starts when you discover, or reasonably should have discovered, the injury and its connection to Shingrix. Product liability limitations periods generally run from one to six years from discovery, depending on the state.11FindLaw. Time Limits for Filing Product Liability Cases State by State
A few states start the clock on the date of the injury itself regardless of when the plaintiff connects it to the vaccine. Alabama, Idaho, Maine, Michigan, and Virginia follow that approach.12Prote Solutio. 50-State Survey of Statutes of Limitations and Repose in Prescription Product Liability Cases Statutes of repose in some states can also bar a claim after a fixed period from the date of sale or manufacture, even if the GBS connection has not yet been made. If you think you have a claim, the deadline analysis should happen early.
What Compensation Might Look Like
No Shingrix GBS verdicts or settlements have been publicly reported. The available reference points come from GBS claims involving other vaccines that went through the VICP, and those figures don’t translate directly to civil litigation against a manufacturer, but they give a sense of the range.
VICP GBS awards have varied widely with the severity and permanence of injury. Cases with limited lasting effects have settled at $70,000 to $150,000.13MCT Law. Results by State More severe or prolonged cases have produced awards from $500,000 to more than $3 million, and one case involving permanent disability from GBS after a flu shot carried a lifetime payout valued at $10 million.14Vaccine Injury Law. Results Recoverable damages in a civil suit typically include medical expenses, lost income, and pain and suffering; the number in any individual case tracks the severity of the injury and the strength of the causation proof.
What Zostavax Litigation Suggests
The nearest precedent is the multidistrict litigation against Merck over Zostavax, the older live-virus shingles vaccine Shingrix replaced. Those cases were consolidated in the Eastern District of Pennsylvania in August 2018 and eventually involved more than 2,000 plaintiffs.15Levin Law. Zostavax Lawsuit
It did not end well for plaintiffs. In March 2022, the court issued a Lone Pine order requiring plaintiffs to produce PCR test results proving their shingles infections came from the vaccine strain rather than the naturally occurring virus. PCR testing had to be done during an active outbreak and wasn’t part of standard care, so most plaintiffs couldn’t comply. In December 2022, Judge Harvey Bartle III dismissed roughly 1,189 cases with prejudice, and the Third Circuit upheld the dismissals. No global settlement was reached, and by 2025 the remaining Zostavax claims were described by legal commentators as approaching zero in value.16Miller & Zois. Settlement Value of Zostavax Shingles Vaccine Cases
Shingrix cases involve a different injury and a different evidentiary problem: separating a vaccine-triggered autoimmune reaction from an infection-triggered one, rather than identifying a viral strain. The individual-causation problem, though, is the same shape. The Zostavax outcome is a reminder that vaccine cases can be won or lost on a single evidentiary requirement the court imposes at the right moment, and that early legal advice about your specific facts matters more than the strength of the general science.